Navigation Links
Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
Date:1/18/2008

SUNNYVALE, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its second quarter 2008 financial results and achievements on Thursday, January 24, 2008, at 4:30 p.m. EDT (1:30 p.m. PDT).

To participate in the conference call, please dial 800-497-0451 for domestic callers and 706-758-3306 for international callers and reference conference passcode, 31926585. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com. The archived version of the webcast will be available on the company's website for one month.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
2. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
3. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Wachovia Foundation Announces $1 Million Each for Atlanta BeltLine Partnership, Center for Civil and Human Rights
5. QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2007
6. QLT Inc. announces initial steps in strategic restructuring
7. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
8. Universal Health Services, Inc. Announces Dividend
9. BD Announces Webcast of Annual Meeting of Shareholders
10. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
11. Chem Rx Announces the Appointment of Three New Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been updated by ... design and the developer has fixed known bugs within the app. Calls Blacklist allows ... phone while not consuming any of their device’s battery power or memory. It provides ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... In response to the opioid abuse epidemic, today ... Medical Products and Tobacco, along with other FDA leaders, called ... to opioid medications. The plan will focus on policies aimed ... access to effective relief. --> ... the risk-benefit paradigm for opioids and ensure that the agency ...
Breaking Medicine Technology: